• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

RF ablation 'biopsy' shows prognostic potential

Article

The histopathology of residual tissue from radiofrequency ablation probes after ablation of hepatocellular carcinomas could predict local tumor progression independently from other tests, according to a study presented at the 2007 Society of Interventional Radiology meeting.

The histopathology of residual tissue from radiofrequency ablation probes after ablation of hepatocellular carcinomas could predict local tumor progression independently from other tests, according to a study presented at the 2007 Society of Interventional Radiology meeting.

Dr. Constantinos T. Sofocleous, an interventional radiologist at Memorial Sloan-Kettering Cancer Center in New York City, and colleagues prospectively classified 55 specimens harvested from RFA probes after liver treatment as coagulation necrosis and 13 as viable tumors. They found that these tissue samples could predict when RFA treatment would not be successful. Primary local tumor progression occurred in 92% of viable tumors versus 29% of those identified by post-RFA biopsy as necrotic. Investigators also found the long-term progression-free interval was about six times greater in the necrotic group. Both findings were statistically significant (p < 0.001).

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.